Tb 149
4.1 h
α 3,97
β+ 1,4...
γ 352, 165...

Chemical properties

Tb-149 is a radiolanthanide, most often in trivalent state and chemically very similar to lutetium. The ionic radius of Tb3+ is 92 pm, i.e. just 7% larger than Lu3+, which explains that macrocyclic chelators suitable for Lu-177 can be directly employed for Tb-149 too, in particular DOTA.

Nuclear properties

Tb-149 decays with a half-life of 4.118(25) hours by 16.7% ɑ decay (3967 keV ɑ) to Eu-145 (T1/2=5.9 d). Moreover, Tb-149 decays by β+ decay (7.1(3)%) and electron capture (76.2%) to Gd-149 (T1/2=5.9 d). It emits a medium energy positron spectrum with 730 keV average energy and 2450 keV maximum energy.

Moreover, Tb-149 emits γ-rays at 165.0 keV (26.4%), 352.2 keV (29.4%), 388.6 keV (18.4%), 652.1 keV (16.2%), 853.4 keV (15.5%), etc.

The mean ɑ energy emitted per decay is 662 keV, the mean ɑ recoil energy 18 keV, the mean electron energy emitted per decay is 84 keV and the mean photon energy per decay is 1286 keV .


Tb-149 is produced by high energy proton induced spallation of tantalum targets at the production facility MEDICIS at CERN. An off-line mass separation is performed at MEDICIS at CERN. The mass-separated ions are implanted into a solid matrix, e.g. an Al, Zn or NaCl layer on a noble metal backing. The implanted layer can be dissolved and used for an additional radiochemical separation to obtain optimum radionuclidic purity by removing the pseudo-isobars Ce-133, Ce-133m, La-133 that are mass-separated as oxide ions on mass 149.


Tb-149 implanted into a solid matrix will be shipped from MEDICIS (CERN, Geneva, Switzerland). To minimize decay losses during shipping, experiments with Tb-149 are best performed at the medical facility AGORA (CHUV, Lausanne, Switzerland).

Examples of use

  • Tb-149 is part of the terbium radionuclide quadruplet .
  • The therapeutic efficacy of Tb-149 has been studied preclinically, labelled to Rituximab or folate respectively .
  • Tb-149 is the only ɑ emitter with clinically useful half-life that is suitable for PET imaging .

Purity grades available


No carrier added (n.c.a.)

Production routeTa(p,spallation)
DaughterDecays to Gd-149 (T1/2=9.3 d, 15 mBq per 1 Bq Tb-149) and Eu-145 (T1/2=5.9 d, 4.8 mBq per 1 Bq Tb-149): 16.7% α, 7.1% β+, 76.2% EC
Half-life4.12 h
ProcessingOff-line mass separation
Primary Container
Product Graden.c.a.
Physical FormSolid
Chemical FormImplanted in solid layer
Radioactive Concentration (gamma spectrometry)n.a.
Radionuclide identification (gamma spectrometry)165 keV, 352 keV and 389 keV gamma lines present
Radionuclidic Purity (gamma spectrometry)n.a.
Chemical purity (ICP-OES)n.a.
Molar activity (ICP-OES)n.a.
Apparent Molar Activityn.a.
Microbiological qualityn.a.
Bacterial endotoxinn.a.
pH (pH strips)n.a.
Additional information
Activity availablet.b.d. (under commissioning), few times per year (planning in advance)
Activity limit for UN2910 (excepted package) shipment0.8 GBq in dry state or 80 MBq in liquid form
Other informationImplanted in Al, Zn or NaCl layer on Au foil


  • α-therapy
  • PET

Point of supply

  • Geneva, Switzerland

Involved production facilities

CERN, International

Involved biomedical facilities

To find out in which biomedical facilities you can use this radionuclide, contact the helpdesk.